Public BoD papers 26.5.22

• Underutilised capacity in theatres – these 2 risks are now redescribed as ‘non delivery of the cancer element of the GM recovery plans’ • Non-delivery of our chemotherapy strategy - redescribed as ‘inequity of access for patients to Christie services due to delays in expanding care closer to home provision’ • Impact of GM pathology on The Christie Pathology Partnership objectives and; • The Christie Pharmacy Company objectives not achieved impacting on clinical service, patient experience and Trust reputation and; • Failure to implement Christie Private Care strategy resulting in detrimental impact on profit share – these 3 risks are now redescribed as ‘not delivering the objectives of our commercial partnerships resulting in negative financial, patient experience or reputational impact’. • Underutilisation of the apprenticeship levy • Risk of non-compliance against PDR target to achieve Trust standard – redescribed as ‘poor workforce engagement impacting on delivery of services’ • Reputational damage as a result of the NHSEI rapid review (November 2020)

3

Suggested updates There are no other suggested updates to the risks identified in the Board Assurance Framework. Consideration will be given to the allocated risks at each Assurance Committee meeting.

4

Recommendation To note the Board Assurance Framework (BAF) 2022/23 that reflects the risks to achievement of the corporate objectives.

96